ArticleCancer reports (Hoboken, N.J.)2025
Assessment of Expression LncRNA-xloc-000303, lncRNA-LOC152578 and hsa-miR-29a in Patients Diagnosed With Colon Cancer in the Pre-Treatment Stage.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of Expression LncRNA-xloc-000303, lncRNA-LOC152578 and hsa-miR-29a in Patients Diagnosed With Colon Cancer in the Pre-Treatment Stage.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEmploying a panel of biomarkers may enable the early diagnosis of colorectal cancer. Among these biomarkers, long non-coding RNAs (LncRNAs) and microRNAs (miRNAs) are significant due to their crucial roles in biological and metabolic processes.
aimsTherefore, the objective of this research was to evaluate the diagnostic value of the biomarkers LncRNA-xloc-000303, lncRNA-LOC152578, and miR-29a in the pre-treatment stage of colorectal cancer in Iranian patients. MATERIALS AND
methodsIn this study, 30 tumor tissue samples and 30 adjacent healthy tissue samples were collected, and RNA was extracted using the Trizol kit. Subsequently, the relative expression of the candidate microRNA and LncRNAs was analyzed using real-time PCR. The obtained gene expression data were then analyzed using REST software.
resultsIn this study, it was found that the expression of LncRNA-xloc-000303 in tumor tissues significantly increased compared to healthy tissue (p < 0.001). Additionally, the analysis revealed that the expression level of lncRNA-LOC152578 showed an increase in tumor tissues compared to healthy tissues (p = 0.57), although these changes were not statistically significant. The results of the hsa-miR-29a expression analysis indicated a down regulation in tumor tissues compared to healthy tissues; however, this change was also not statistically significant (p = 0.34).
conclusionThe results indicated that the expression changes of LncRNA-xloc-000303 in cancer tissue were significant compared to adjacent healthy tissue, suggesting its potential use as a biomarker for diagnosing colorectal cancer. However, further studies are needed to evaluate the biomarker specificity of lncRNA-LOC152578 and hsa-miR-29a. This study was conducted in an Iranian population and its results can be used in the future for personalized medicine in the prevention and treatment of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.